Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,973 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Loss of p16 expression is of prognostic significance in locally advanced prostate cancer: an analysis from the Radiation Therapy Oncology Group protocol 86-10.
Chakravarti A, Heydon K, Wu CL, Hammond E, Pollack A, Roach M, Wolkov H, Okunieff P, Cox J, Fontanesi J, Abrams R, Pilepich M, Shipley W; Radiation Therapy Oncology Group. Chakravarti A, et al. Among authors: wu cl. J Clin Oncol. 2003 Sep 1;21(17):3328-34. doi: 10.1200/JCO.2003.12.151. J Clin Oncol. 2003. PMID: 12947069
Expression of the epidermal growth factor receptor and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based chemotherapy: a report from the Radiation Therapy Oncology Group.
Chakravarti A, Winter K, Wu CL, Kaufman D, Hammond E, Parliament M, Tester W, Hagan M, Grignon D, Heney N, Pollack A, Sandler H, Shipley W. Chakravarti A, et al. Among authors: wu cl. Int J Radiat Oncol Biol Phys. 2005 Jun 1;62(2):309-17. doi: 10.1016/j.ijrobp.2004.09.047. Int J Radiat Oncol Biol Phys. 2005. PMID: 15890569
Multidisciplinary care and pursuit of active surveillance in low-risk prostate cancer.
Aizer AA, Paly JJ, Zietman AL, Nguyen PL, Beard CJ, Rao SK, Kaplan ID, Niemierko A, Hirsch MS, Wu CL, Olumi AF, Michaelson MD, D'Amico AV, Efstathiou JA. Aizer AA, et al. Among authors: wu cl. J Clin Oncol. 2012 Sep 1;30(25):3071-6. doi: 10.1200/JCO.2012.42.8466. Epub 2012 Jul 30. J Clin Oncol. 2012. PMID: 22851571
Bladder preservation therapy for muscle-invading bladder cancers on Radiation Therapy Oncology Group trials 8802, 8903, 9506, and 9706: vascular endothelial growth factor B overexpression predicts for increased distant metastasis and shorter survival.
Lautenschlaeger T, George A, Klimowicz AC, Efstathiou JA, Wu CL, Sandler H, Shipley WU, Tester WJ, Hagan MP, Magliocco AM, Chakravarti A. Lautenschlaeger T, et al. Among authors: wu cl. Oncologist. 2013 Jun;18(6):685-6. doi: 10.1634/theoncologist.2012-0461. Epub 2013 May 31. Oncologist. 2013. PMID: 23728940 Free PMC article.
Transurethral surgery and twice-daily radiation plus paclitaxel-cisplatin or fluorouracil-cisplatin with selective bladder preservation and adjuvant chemotherapy for patients with muscle invasive bladder cancer (RTOG 0233): a randomised multicentre phase 2 trial.
Mitin T, Hunt D, Shipley WU, Kaufman DS, Uzzo R, Wu CL, Buyyounouski MK, Sandler H, Zietman AL. Mitin T, et al. Among authors: wu cl. Lancet Oncol. 2013 Aug;14(9):863-72. doi: 10.1016/S1470-2045(13)70255-9. Epub 2013 Jul 1. Lancet Oncol. 2013. PMID: 23823157 Free PMC article. Clinical Trial.
Bladder Preservation With Twice-a-Day Radiation Plus Fluorouracil/Cisplatin or Once Daily Radiation Plus Gemcitabine for Muscle-Invasive Bladder Cancer: NRG/RTOG 0712-A Randomized Phase II Trial.
Coen JJ, Zhang P, Saylor PJ, Lee CT, Wu CL, Parker W, Lautenschlaeger T, Zietman AL, Efstathiou JA, Jani AB, Kucuk O, Souhami L, Rodgers JP, Sandler HM, Shipley WU. Coen JJ, et al. Among authors: wu cl. J Clin Oncol. 2019 Jan 1;37(1):44-51. doi: 10.1200/JCO.18.00537. Epub 2018 Nov 15. J Clin Oncol. 2019. PMID: 30433852 Free PMC article. Clinical Trial.
MicroRNA Biomarkers for Patients With Muscle-Invasive Bladder Cancer Undergoing Selective Bladder-Sparing Trimodality Treatment.
Meng W, Efstathiou J, Singh R, McElroy J, Volinia S, Cui R, Ibrahim A, Johnson B, Gupta N, Mehta S, Wang H, Miller E, Nguyen P, Fleming J, Wu CL, Haque SJ, Shipley W, Chakravarti A. Meng W, et al. Among authors: wu cl. Int J Radiat Oncol Biol Phys. 2019 May 1;104(1):197-206. doi: 10.1016/j.ijrobp.2018.12.028. Epub 2018 Dec 21. Int J Radiat Oncol Biol Phys. 2019. PMID: 30583038
Impact of Immune and Stromal Infiltration on Outcomes Following Bladder-Sparing Trimodality Therapy for Muscle-Invasive Bladder Cancer.
Efstathiou JA, Mouw KW, Gibb EA, Liu Y, Wu CL, Drumm MR, da Costa JB, du Plessis M, Wang NQ, Davicioni E, Feng FY, Seiler R, Black PC, Shipley WU, Miyamoto DT. Efstathiou JA, et al. Among authors: wu cl. Eur Urol. 2019 Jul;76(1):59-68. doi: 10.1016/j.eururo.2019.01.011. Epub 2019 Feb 1. Eur Urol. 2019. PMID: 30712971 Free PMC article.
1,973 results